AllianceBernstein
HARP

AllianceBernstein’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

AllianceBernstein’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,320
Closed -$115K – 3433
2022
Q1 		$115K Hold
2,320
– – ﹤0.01% 3099
2021
Q4 		$175K Sell
2,320
-290
-11% -$19.8K ﹤0.01% 3111
2021
Q3 		$206K Hold
2,610
– – ﹤0.01% 3080
2021
Q2 		$362K Buy
2,610
+1,080
+71% +$206K ﹤0.01% 2954
2021
Q1 		$320K Sell
1,530
-270
-15% -$54.1K ﹤0.01% 2874
2020
Q4 		$299K Hold
1,800
– – ﹤0.01% 2851
2020
Q3 		$306K Buy
1,800
+140
+8% +$20.2K ﹤0.01% 2801
2020
Q2 		$276K Buy
+1,660
New +$259K ﹤0.01% 2915

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's HARP Position: Q2 2022 in Review

AllianceBernstein sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 2,320 shares — an estimated $115K sold.

AllianceBernstein first reported a position in HARP in Q2 2020 and held it in 8 quarters. The position peaked at $362K in Q2 2021. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • AllianceBernstein reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • AllianceBernstein sold 2,320 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $115K.
  • AllianceBernstein first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • AllianceBernstein's Harpoon Therapeutics, Inc. Common Stock position peaked at $362K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.